Tirzepatide attenuates mammary tumor progression in diet-induced obese mice.

Autor:	Glenny EM; Department of Nutrition, University of North Carolina, Chapel Hill, NC, USA., Ho AN; Department of Nutrition, University of North Carolina, Chapel Hill, NC, USA., Kiesel VA; Department of Nutrition, University of North Carolina, Chapel Hill, NC, USA., Chen F; Department of Nutrition, University of North Carolina, Chapel Hill, NC, USA., Gates CE; Department of Nutrition, University of North Carolina, Chapel Hill, NC, USA., Paules EM; Department of Nutrition, University of North Carolina, Chapel Hill, NC, USA., Xu R; Department of Nutrition, University of North Carolina, Chapel Hill, NC, USA., Holt CA; Department of Nutrition, University of North Carolina, Chapel Hill, NC, USA., Coleman MF; Department of Nutrition, University of North Carolina, Chapel Hill, NC, USA., Hursting SD; Department of Nutrition, University of North Carolina, Chapel Hill, NC, USA.
Jazyk:	angličtina
Zdroj:	BioRxiv : the preprint server for biology [bioRxiv] 2024 Jan 23. Date of Electronic Publication: 2024 Jan 23.
DOI:	10.1101/2024.01.20.576484
Abstrakt:	We report for the first time an anticancer benefit of tirzepatide-a dual glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide receptor agonist-in a model of obesity and breast cancer in female mice. Long-term tirzepatide treatment induced weight loss, mitigated obesity-driven changes in circulating metabolic hormone levels, and suppressed orthotopic E0771 mammary tumor growth. Relative to tirzepatide, chronic calorie restriction, an established anticancer intervention in preclinical models, promoted even greater weight loss, systemic hormonal regulation, and tumor suppression. We conclude that tirzepatide represents a promising pharmacologic approach for mitigating the procancer effects of obesity. Moreover, strategies promoting greater weight loss than achieved with tirzepatide alone may augment the anticancer benefits of tirzepatide. Competing Interests: Disclosures: The authors have no conflicts of interest.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu